mitochondrial inner membrane protein MPV17Genealiases: CMT2EE · MTDPS6 · SYM1
Q-omics provides the consensus-scored MPV17 profile across patient tissues and cancer cell-line models. MPV17 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MPV17 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MPV17 RNA expression shows 18,417 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight UVM, KIRC, and DLBC as cancer lineages where MPV17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MPV17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MPV17 survival associations across molecular data types. MPV17 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MPV17 RNA expression–survival associations across cancer types. High MPV17 expression shows unfavorable associations in UVM, LIHC, STAD, LGG and BLCA, but favorable associations in THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MPV17 RNA expression.
This table summarizes MPV17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MPV17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MPV17 shows higher tumor expression in KIRC, HNSC, COAD, LIHC, KIRP and THCA. The KIRC box plot shows higher MPV17 RNA expression in tumor versus normal tissue (log2 FC = +1.089, t-test p < 0.001).
This table shows molecular features associated with MPV17 in patient tissues and cancer cell lines. In patient samples, MPV17 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, MPV17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Lymphoma.
